Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: muscle
- Who it enrolls
- age 18 Years to 65 Years; excludes diabetes; BMI ≥27 required; conditions: Obesity; Sarcopenia; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- Interventions
- Resistance exercise; Lifestyle recommendations
- Conditions
- Obesity; Sarcopenia; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- Phase and size
- NA · 108 participants
- Dates
- Start 2026-11-01
Primary completion 2027-11-30 - Sponsor
- Acibadem University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in muscle thicknessBaseline, 12 weeks, 24 weeks
- Muscle echo intensityBaseline, 12 weeks, 24 weeks
02Eligibility
Who can take part
Inclusion Criteria: * initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist, * body mass index (BMI) ≥27 kg/m² and the presence of a comorbidity condition or BMI≥30 kg/m² * age between 18 and 65 years Exclusion Criteria: * diagnosis of type 1 or type 2 diabetes mellitus * presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders * current participation in a structured diet or exercise program * use of weight-loss medications within the past 12 months * history of upper or lower extremity surgery or injury within the past 6 months * any contraindication to resistance exercise as determined by the treating physician.
03Change log
Registry changes
No changes recorded since the trial was added.